CLAIMS

1. A compound of the formulae:



, or ,

wherein:

A is selected from optionally substituted saturated, partly saturated or unsaturated 5- or 6-membered heterocyclyl; optionally substituted C_{1-6}alkoxyl amine; optionally substituted C_{1-6}alkyl amine; optionally substituted C_{0-6}alkyl carboxylic acid; optionally substituted C_{1-6}alkyl hydroxyl; optionally substituted saturated or unsaturated C_{0-6}alkyl bicyclic heterocyclyl; and optionally substituted saturated or unsaturated C_{1-6}alkoxyl bicyclic heterocyclyl,

or a pharmacologically acceptable salt, stereoisomer, diastereomer, enantiomer, racemate, hydrate and/or solvate thereof.

2. The compound according to claim 1, wherein the saturated, partly saturated or unsaturated 5- or 6-membered heterocyclyl contains one or more of N, S or O, optionally substituted with one or more oxo, C_{1-6}alkyl, amino, hydroxyl or halo substituents.

3. The compound according to claim 1, wherein the saturated, partly saturated or unsaturated 5- or 6-membered heterocyclyl is selected from pyrrolyl, pyrazolyl, imidazolyl, triazolyl, imidazolidinyl, pyrrolidinyl, pyrrolidinylidene, dihydropyrrolyl, isoxazolyl dihydrooxazolyl, isoxazolidinyl, oxazolidinyl and oxazolyl, optionally substituted with one or more oxo, C_{1-6}alkyl, amino, hydroxyl or halo substituents.

4. The compound according to claim 1, wherein the C_{1-6}alkoxyl amine is aminooxymethyl.

5. The compound according to claim 1, wherein the C_{1-6}alkyl amine is optionally substituted with one or more of C_{1-6}alkyl, C_{1-6}halo alkyl, hydroxyl or halo, preferably mono-, di- or tri-substituted halo alkyl, most preferably tri-fluoro methane.

6. The compound according to claim 1, wherein the C_{0-6}alkyl carboxylic acid is carboxylic acid.

7. The compound according to claim 1, wherein the C_{1-6}alkyl hydroxyl is methyl hydroxyl.

8. The compound according to claim 1, wherein the C_{0-6}alkyl bicyclic heterocyclyl is selected from indolyl, isoindolyl, insolinyl and isoindolinyl, optionally substituted with one or more oxo, preferably dioxo.

9. The compound according to claim 1, wherein the C_{1-6}alkoxyl bicyclic heterocyclyl is selected indolyl, isoindolyl, insolinyl and isoindolinyl, optionally substituted with one or more oxo, and wherein the C_{1-6}alkoxyl is methoxy or ethoxy.

10. The compound according to claim 1, wherein A is selected from:


,

,

,

,

,

,

,

,


, 
, 
, 
and 
.

11. The compound according to any one of claims 1 to 10, wherein the compound is selected from the group consisting of:


(**A32**), 
(**A6**), 
(**A26**),


(**A27**), 
(**A30**), 
(**A31**),



(**A35**),



(**A45**),



(**A56**),



(**A79**),



(**A56k**),



(**A56f**),



(**A81**) and



(**A56g**),

or a pharmacologically acceptable salt, stereoisomer, diastereomer, enantiomer, racemate, hydrate and/or solvate thereof.

12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11 and a pharmaceutically acceptable excipient.

13. Use of a compound according to any one of claims 1 to 11 for the manufacture of a medicament for the treatment of fibrosis.

14. The use according to claim 13, wherein the medicament prevents, reduces or slows the progression of fibrosis.

15. The use according to claim 13, wherein the medicament reduces established fibrosis.

16. The use according to claim 13, wherein the medicament restores normal tissue architecture.

17. The use according to any one of claims 13 to 16, wherein the fibrosis is myocardial fibrosis, kidney fibrosis and/or liver fibrosis.

18. Use of a compound according to any one of claims 1 to 11 for the manufacture of a medicament for preventing, reducing or slowing fat accumulation in the liver.

19. Use of a compound according to any one of claims 1 to 11 for the manufacture of a medicament for preventing, reducing or slowing renal tubular cell death.

20. Use of a compound according to any one of claims 1 to 11 for the manufacture of a medicament for restoring normal tissue architecture.

21. A compound of the formula:



.